We are live on ! Find out more
RPRX icon

Royalty Pharma
RPRX

447 hedge funds and large institutions have $10.1B invested in Royalty Pharma in 2025 Q1 according to their latest regulatory filings, with 84 funds opening new positions, 160 increasing their positions, 149 reducing their positions, and 50 closing their positions.

New
Increased
Maintained
Reduced
Closed

160% more call options, than puts

Call options by funds: $89M | Put options by funds: $34.2M

68% more first-time investments, than exits

New positions opened: 84 | Existing positions closed: 50

22% more capital invested

Capital invested by funds: $8.21B → $10.1B (+$1.84B)

7% more funds holding

Funds holding: 416 → 447 (+31)

2.07% more ownership

Funds ownership: 72.43% → 74.49% (+2.1%)

7% more repeat investments, than reductions

Existing positions increased: 160 | Existing positions reduced: 149

22% less funds holding in top 10

Funds holding in top 10: 9 → 7 (-2)

Holders
447
Holders Change
+31
Holders Change %
+7.45%
% of All Funds
5.99%
Holding in Top 10
7
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-22.22%
% of All Funds
0.09%
New
84
Increased
160
Reduced
149
Closed
50
Calls
$89M
Puts
$34.2M
Net Calls
+$54.8M
Net Calls Change
+$39.9M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$413M
2
CIA
Caledonia Investments (Australia)
Australia
+$162M
3
Victory Capital Management
Victory Capital Management
Texas
+$83.8M
4
Morgan Stanley
Morgan Stanley
New York
+$47.5M
5
Los Angeles Capital Management
Los Angeles Capital Management
California
+$33M

Top Sellers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$340M
2
Millennium Management
Millennium Management
New York
-$66.8M
3
SGA
Siguler Guff Advisers
New York
-$60.4M
4
Deutsche Bank
Deutsche Bank
Germany
-$56.3M
5
Viking Global Investors
Viking Global Investors
Connecticut
-$52.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
TFA
376
Transamerica Financial Advisors
Florida
$45K -$15.7K -496 -26%
WA
377
WPG Advisers
Maryland
$39.5K +$1.77K +56 +5%
RTC
378
Riverview Trust Company
Washington
$37.9K – – –
SWM
379
Spire Wealth Management
Virginia
$37.2K -$30.2K -954 -44%
SSG
380
Summit Securities Group
New York
$36.2K +$36.9K +1,163 New
BIG
381
Brooklyn Investment Group
New York
$36K +$6.18K +195 +20%
GWM
382
Geneos Wealth Management
Colorado
$29.9K +$25.6K +809 +539%
MPWT
383
MassMutual Private Wealth & Trust
Connecticut
$29.8K +$13.1K +414 +76%
PWAM
384
Private Wealth Asset Management
Iowa
$29.5K +$30K +948 New
LC
385
Lindbrook Capital
California
$29.2K -$16.1K -509 -35%
LI
386
Louisbourg Investments
New Brunswick, Canada
$28.2K +$28.7K +905 New
TWD
387
True Wealth Design
Ohio
$26.3K +$1.43K +45 +6%
HCP
388
Hexagon Capital Partners
Arkansas
$22.3K +$32 +1 +0.1%
ACA
389
American Capital Advisory
Idaho
$21.9K +$127 +4 +0.6%
FFA
390
Farther Finance Advisors
California
$20.8K +$983 +31 +5%
RS
391
Rakuten Securities
Japan
$20K -$31.3K -986 -61%
PFBT
392
Parkside Financial Bank & Trust
Missouri
$19.7K +$7K +221 +54%
ZRP
393
Zynergy Retirement Planning
New Jersey
$19.1K – – –
HNB
394
Huntington National Bank
Ohio
$19.1K +$2.28K +72 +13%
AssetMark Inc
395
AssetMark Inc
California
$18.9K +$8.56K +270 +80%
MCM
396
Manchester Capital Management
Vermont
$18.1K +$5.55K +175 +43%
VCM
397
Versant Capital Management
Arizona
$15K +$11.4K +361 +301%
QCG
398
Quadrant Capital Group
Ohio
$14.8K +$2.82K +89 +23%
CA
399
Continuum Advisory
Idaho
$13.3K +$13.6K +428 New
GXJ
400
Global X Japan
Japan
$12.9K -$1.43K -45 -10%
14 15
16
17 18

RPRX Hedge Fund Activity: Q1 2025 in Review

447 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q1 2025, worth a combined $10.1B — up 22% from $8.21B a quarter earlier.

Buyers outnumbered sellers: 84 funds opened new RPRX positions and 50 closed out — a net gain of 34 holders — while 160 added to existing stakes and 149 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $413M. The largest seller was Adage Capital Partners, cutting an estimated $340M.

  • 447 institutional investors held Royalty Pharma (RPRX) as of Q1 2025, up from 416 in Q4 2024.
  • Funds reported $10.1B of Royalty Pharma stock for Q1 2025, up 22% quarter-over-quarter.
  • 84 funds opened new Royalty Pharma positions in Q1 2025 and 50 closed out, a net change of +34 holders.
  • The largest Royalty Pharma buyer in Q1 2025 was Fidelity Investments, an estimated $413M added.
  • The largest Royalty Pharma seller in Q1 2025 was Adage Capital Partners, an estimated $340M sold.

Based on aggregated 13F filings for Q1 2025.